Adaptive Data Reconciliation Coupling C plus plus and PRO/II and On-line Application by the Field

被引：0
|
作者：
Manenti, Flavio [1 ]
Signor, Stefano [2 ]
Grottoli, Maria Grazia [2 ]
Fabbri, Paolo [2 ]
机构：
[1] Politecn Milan, CMIC Dept Giulio Natta, Piazza Leonardo da Vinci 32, I-20133 Milan, Italy
[2] Chemprod Srl Automat & Proc Solut, I-20129 Milan, Italy
来源：
20TH EUROPEAN SYMPOSIUM ON COMPUTER AIDED PROCESS ENGINEERING | 2010年 / 28卷
关键词：
Adaptive Data Reconciliation; Parameter Estimation; Sulfur Recovery; OPTIMIZATION; MODELS;
D O I：
暂无
中图分类号：
TQ [化学工业];
学科分类号：
0817 ;
摘要：
The paper discusses the possibility of coupling object-oriented programming languages such as Visual C++ and the commercial simulators such as PRO/II, UniSim, and AspenHysys to get a generalized framework for robust and reliable data reconciliation of sulfur recovery units by taking to a series of benefits from their interaction: (i) simulation software provides a high-level and field-proven degree of detail in simulating processes; (ii) they usually allow inferring measures even when the instrumentation presents serious lacks by the field; and (iii) the programming languages allow using specific numerical libraries to solve large-scale, nonlinear, constrained optimization problems by making them feasible even for the on-line industrial application. The proposed approach was validated on a large-scale Sulfur Recovery Unit (technology by Technip-KTI SpA) operating in an oil refinery placed in Italy.
引用
收藏
页码：373 / 378
页数：6
相关论文
共 50 条
  • [31] Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JS']JSWOG-C3 study)
    Mori, Y.
    Suzuki, N.
    Nagasaka, T.
    Tanioka, H.
    Iwamoto, Y.
    Neki, Y.
    Yamatsuji, T.
    Kobayashi, M.
    Nakajima, M.
    Ojima, Y.
    Ikeda, S.
    Kawamoto, K.
    Shinozaki, K.
    Tsuji, A.
    Hinoi, T.
    Yamaguchi, Y.
    Yamashita, K.
    Shimokawa, M.
    Okajima, M.
    Hazama, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] DOCETAXEL-PREDNISONE (DP) PLUS METRONOMIC CYCLOPHOSPHAMIDE (CTX) AND CELECOXIB (C) AS FIRST LINE TREATMENT IN CASTRATION RESISTANT PROSTATE CANCER (CRPC): PHASE II TRIAL WITH PHARMACODYNAMIC EVALUATION
    Fontana, A.
    Galli, L.
    Derosa, L.
    Minuti, G.
    D'Arcangelo, M.
    Fontana, E.
    Di Marsico, R.
    Venditti, O.
    Galluzzo, S.
    Landi, L.
    Bursi, S.
    Galli, C.
    Bona, E.
    Bocci, G.
    Antonuzzo, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
  • [33] Phase II COLET study: Atezolizumab (A) plus cobimetinib (C) plus paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
    Brufsky, Adam
    Kim, Sung-Bae
    Zvirbule, Zanete
    Dirix, Luc Yves
    Eniu, Alexandru E.
    Carabantes, Francisco
    Izarzugaza, Yann
    Mebis, Jeroen
    Sohn, Joohyuk
    Wongchenko, Matthew
    Chohan, Saibah
    Amin, Reena
    McNally, V. A.
    Miles, David
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma
    Bi, Feng
    Zhang, Yan-Qiao
    Gu, Shanzhi
    Guo, Yabing
    Xu, Zhongyuan
    Ying, Hao
    Da, Mingxu
    Liu, Chaoying
    Pan, Yaozhen
    Huang, Yao
    Chen, Zhiyu
    Wang, Zheng
    Wu, Jianbing
    Weng, Shangeng
    Wang, Yanjun
    Zhao, Jun
    Yu, Xiaokui
    Li, Hui
    Xue, Shilin
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and individual limiting toxicity syndromes prediction by pharmacogenomic biomarkers
    Bruera, G.
    Massacese, S.
    Pepe, F.
    Malapelle, U.
    Dal Mas, A.
    Ciacco, E.
    Calvisi, G.
    Marchetti, P.
    Troncone, G.
    Simmaco, M.
    Ricevuto, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [36] Updated data from FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer, an open-label, single-arm, phase 2 trial
    Chen, Li
    Jiang, Yi-Zhou
    Wu, Songyang
    Wu, Jiong
    Di, Genhong
    Liu, Guangyu
    Yu, Keda
    Fan, Lei
    Li, Junjie
    Hou, Yifeng
    Hu, Zhen
    Chen, Canming
    Huang, Xiaoyan
    Cao, Ayong
    Hu, Xin
    Zhao, Shen
    Ma, Xiaoyan
    Zhu, Xiaoyu
    Zou, Jianjun
    Yang, Wentao
    Wang, Zhonghua
    Shao, Zhi-ming
    CANCER RESEARCH, 2022, 82 (04)
  • [37] Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.
    Bruera, Gemma
    Massacese, Silvia
    Pepe, Francesco
    Malapelle, Umberto
    Dal Mas, Antonella
    Ciacco, Eugenio
    Calvisi, Giuseppe
    Marchetti, Paolo
    Troncone, Giancarlo
    Simmaco, Maurizio
    Ricevuto, Enrico
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
    Bruera, Gemma
    Massacese, Silvia
    Pepe, Francesco
    Malapette, Umberto
    Mas, Antonella Dat
    Ciacco, Eugenio
    Calvisi, Giuseppe
    Troncone, Giancarlo
    Simmaco, Maurizio
    Ricevuto, Enrico
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [39] Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD plus C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS
    Houot, R.
    Le Gouill, S.
    Uribe, M. Ojeda
    Mounier, C.
    Courby, S.
    Dartigeas, C.
    Bouabdallah, K.
    Vigier, M. Alexis
    Moles, M. P.
    Tournilhac, O.
    Arakelyan, N.
    Rodon, P.
    El Yamani, A.
    Sutton, L.
    Fornecker, L.
    Assouline, D.
    Harousseau, J. L.
    Maisonneuve, H.
    Caulet-Maugendre, S.
    Gressin, R.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1555 - 1561
  • [40] Final Results of-the RiPAD plus C Regimen Including Velcade In Front Line Therapy for Elderly Patients with-Mantle Cell Lymphoma. A Phase II Prospective Study of the GOELAMS Group
    Gressin, Remy
    Houot, Roch
    Uribe, Mario Ojeda
    Mounier, Christiane
    Bouabdallah, Krimo
    Alexis, Magda
    Senecal, Delphine
    Molless, Marie Pierre
    Tournilhac, Olivier
    Park, Sophie
    Rodon, Philippe
    El Yamani, Abderrazak
    Sutton, Laurent
    Lioure, Bruno
    Assouline, David
    Harousseau, Jean-Luc
    Maisonneuve, Herve
    Maugendre, Sylvie-Caulet
    Le Gouill, Steven
    BLOOD, 2010, 116 (21) : 1150 - 1150
12345